Peter Thiel, Marc Andreessen and Joe Lonsdale are among the investors backing venture debt firm Tacora Capital https://t.co/jb65xL4UfR ...

Group 1: Overview of Ares Capital Corporation (ARCC) - Ares Capital focuses on middle-market firms across various industries, providing debt financing ranging from $30 million to $500 million [6][9] - As of March 31, 2025, ARCC had a diversified investment portfolio of $27.1 billion across 566 portfolio companies, with significant investments in software & services (24%) and healthcare equipment & services (13%) [9][12] - In Q1 2025, ARCC reported a 4.4% year-over-year growth in total investment income, driven by increased interest income, but faced lower portfolio exits and gross commitments [7][12] Group 2: Overview of Hercules Capital, Inc. (HTGC) - Hercules Capital specializes in venture debt, targeting high-growth technology and life sciences sectors, with investments generally ranging from $15 million to $40 million [15][20] - As of March 31, 2025, HTGC had an investment portfolio of $3.9 billion, with 32% in software companies and 29% in drug discovery & development [20][23] - In Q1 2025, HTGC experienced a 2% decline in total investment income but recorded a rise in gross new debt and equity commitments [16][23] Group 3: Financial Performance and Growth Outlook - Ares Capital's total investment income has seen a CAGR of 14.4% over the last five years, with significant gross investment commitments in recent years [8][12] - Hercules Capital's total investment income has a CAGR of 12.1% over the last decade, with increasing demand for customized financing expected to drive future growth [16][17] - Analysts have revised earnings estimates downward for ARCC, indicating a 12% decline for 2025, while HTGC's earnings are expected to decline by 4% in 2025 but grow by 5.9% in 2026 [26][38] Group 4: Valuation and Comparison - Ares Capital is currently trading at a forward P/E of 10.54X, higher than its five-year median of 9.36X, while Hercules Capital trades at a forward P/E of 8.83X, lower than its five-year median of 9.39X [30][33] - Hercules Capital has a return on equity (ROE) of 16.84%, significantly higher than ARCC's 11.05% and the industry average of 11.20% [33][37] - HTGC's dividend yield of 9.23% is slightly higher than ARCC's 8.92%, although both are below the industry average of 10.27% [35][37]

Financial Data and Key Metrics Changes - The company generated net investment income (NII) of $0.27 per share, unchanged from the previous quarter but down from $0.38 per share in the same quarter last year [27] - The net asset value (NAV) decreased to $7.57 per share from $8.43 at the end of the previous quarter and $9.64 a year ago, primarily due to fair value adjustments and distributions [28] - Investment income for the first quarter was $25 million, a slight decrease from $26 million in the prior year period, attributed to lower interest and fee income [25] Business Line Data and Key Metrics Changes - The total investment portfolio at the end of the first quarter stood at $690 million, with debt investments in 53 companies valued at $644 million and equity investments in 110 companies valued at $46 million [27] - New originations totaled $102 million, offset by $11 million in scheduled principal payments and $68 million in prepayments [27] - The debt portfolio yield was 15%, slightly down from 15.6% in the same quarter last year, while onboarding yields were 13%, up from 12.6% in the previous quarter [25][12] Market Data and Key Metrics Changes - Approximately $92 billion was invested in VC-backed companies in the first quarter, a 19% increase from the previous quarter, driven largely by significant AI deals [18] - The S&P Biotech Select Industry Index is down 14% year-over-year, indicating cooling investor sentiment in the life sciences market [19] - The exit market for VC-backed tech and life science companies remains nearly shut due to macroeconomic uncertainties, impacting the overall venture capital ecosystem [20] Company Strategy and Development Direction - The company aims to grow its portfolio while maintaining a focus on high-quality, well-sponsored tech and life science companies [20] - The management remains selective in originating loans due to the current macro environment, with a commitment to optimizing returns from stressed investments [16] - The partnership with Monroe Capital is expected to provide additional capital and scale, enhancing the company's ability to navigate current market challenges [9] Management's Comments on Operating Environment and Future Outlook - Management expressed guarded optimism for the year despite recent macroeconomic headwinds, including tariff-related uncertainties impacting recovery from stressed assets [5] - The company anticipates that as the macro environment normalizes, it will be positioned to grow its portfolio and increase NII to cover distributions over time [16] - Management highlighted the importance of maintaining a strong liquidity position, with $126 million in available liquidity as of March 31 [23] Other Important Information - The company declared regular monthly distributions of $0.11 per share through September 2025, supported by undistributed spillover income of $1 per share [27] - The advisor has agreed to waive a portion of its quarterly income incentive fees if NII falls below declared distributions [7] - The company is actively managing its portfolio to optimize returns and mitigate risks associated with stressed investments [15] Q&A Session Summary Question: How is the company managing spillover earnings in the current uncertain environment? - Management indicated that they plan to continue growing distributions through 2025 and will manage spillover earnings quarterly, reviewing them in discussions with the board [32][34] Question: What is the quality of deals currently being pursued? - Management noted a higher bar for selecting transactions, focusing on companies performing well operationally and backed by quality VCs, while being selective due to the current market conditions [36][38] Question: Is there a plan to raise leverage ratios to grow the portfolio? - The target leverage ratio is around 1.2x to 1.3x, with the current ratio at 1.29x, indicating a cautious approach to leverage [42][43] Question: How does the company plan to address the high dividend payout relative to debt yields? - Management stated that they review equity needs and funding pipelines quarterly, considering the balance between dividends and investment returns [47][48] Question: What is the impact of tariffs on the portfolio? - Management indicated that while there is some uncertainty due to tariffs, most portfolio companies have planned for potential impacts, and the overall effect has been more about market volatility than specific tariff issues [65][66] Question: What resources are available from the recent Monroe partnership? - The partnership is expected to provide support in stabilizing and growing the business, with ongoing collaboration to enhance operational effectiveness [68][69]

Runway Growth Finance Corp. (NASDAQ:RWAY) Q4 2024 Earnings Conference Call March 20, 2024 5:00 PM ET Company Participants Quinlan Abel - Assistant VP, IR David Spreng - Chairman and CEO Greg Greifeld - CIO, Runway Growth Capital Tom Raterman - CFO and COO Conference Call Participants Casey Alexander - Compass Point Research & Trading Finian O'Shea - Wells Fargo Melissa Wedel - JPMorgan Cory Johnson - UBS Erik Zwick - Lucid Capital Markets Operator Ladies and gentlemen, thank you for standing by and welcome ...